Axon Enterprise (NASDAQ:AXON) Downgraded to Neutral Rating by Northcoast Research

Axon Enterprise (NASDAQ:AXON) was downgraded by stock analysts at Northcoast Research from a “buy” rating to a “neutral” rating in a research report issued on Wednesday,Briefing.com Automated Import reports.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Robert W. Baird increased their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. TD Cowen assumed coverage on shares of Axon Enterprise in a research note on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. Needham & Company LLC increased their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, JMP Securities increased their target price on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 4th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $542.15.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $710.01 on Wednesday. Axon Enterprise has a 1 year low of $260.27 and a 1 year high of $715.99. The company has a market capitalization of $54.14 billion, a PE ratio of 183.47, a P/E/G ratio of 6.85 and a beta of 1.05. The company has a fifty day moving average of $625.48 and a two-hundred day moving average of $514.81. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 1,035 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $624.47, for a total value of $646,326.45. Following the completion of the transaction, the insider now directly owns 124,243 shares of the company’s stock, valued at approximately $77,586,026.21. This trade represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the transaction, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,711 shares of company stock valued at $5,631,561. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Public Sector Pension Investment Board increased its stake in shares of Axon Enterprise by 19.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock worth $1,240,000 after purchasing an additional 500 shares in the last quarter. CIBC Asset Management Inc increased its stake in shares of Axon Enterprise by 9.2% during the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after purchasing an additional 895 shares in the last quarter. Foundations Investment Advisors LLC purchased a new position in shares of Axon Enterprise during the 3rd quarter worth approximately $221,000. Sequoia Financial Advisors LLC increased its stake in shares of Axon Enterprise by 4.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 81 shares in the last quarter. Finally, Axxcess Wealth Management LLC purchased a new position in shares of Axon Enterprise during the 3rd quarter worth approximately $814,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.